Sfoglia per AUTORE
DORFF T
Collezione AOU San Luigi di Orbassano
Items : 3
Patient-reported Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Harboring DNA Damage Response Alterations Treated with Talazoparib: Results from TALAPRO-1. in European urology / Eur Urol. 2023 Apr;83(4):352-360. doi: 10.1016/j.eururo.2022.05.030. Epub 2022 Jun 22.
2023
AOU San Luigi di Orbassano
AOU San Luigi di Orbassano
Healy C; Bhattacharyya H; Gurney H; Maruzzo M; Higano CS; Renard V; Machiels JP; Stirling A; Scagliotti G; Mehra N; Dorff T; Barthélémy P; de Bono J; Saad F; Arondekar B; Niyazov A; Fizazi K;
Talazoparib, a Poly(ADP-ribose) Polymerase Inhibitor, for Metastatic Castration-resistant Prostate Cancer and DNA Damage Response Alterations: TALAPRO-1 Safety Analyses. in The oncologist / Oncologist. 2022 Oct 1;27(10):e783-e795. doi: 10.1093/oncolo/oyac172.
2022
AOU San Luigi di Orbassano
AOU San Luigi di Orbassano
Mehra N; Fizazi K; de Bono JS; Barthélémy P; Dorff T; Stirling A; Machiels JP; Bimbatti D; Kilari D; Dumez H; Buttigliero C; van Oort IM; Castro E; Chen HC; Di Santo N; DeAnnuntis L; Healy CG; Scagliotti GV;
Talazoparib monotherapy in metastatic castration-resistant prostate cancer with DNA repair alterations (TALAPRO-1): an open-label, phase 2 trial. in The Lancet. Oncology / Lancet Oncol. 2021 Sep;22(9):1250-1264. doi: 10.1016/S1470-2045(21)00376-4. Epub 2021 Aug 10.
2021
AOU San Luigi di Orbassano
AOU San Luigi di Orbassano
de Bono JS; Mehra N; Scagliotti GV; Castro E; Dorff T; Stirling A; Stenzl A; Fleming MT; Higano CS; Saad F; Buttigliero C; van Oort IM; Laird AD; Mata M; Chen HC; Healy CG; Czibere A; Fizazi K;